Zura Bio Limited (NasdaqCM: ZURA)
Health Care · Biotechnology · US
$5.85
+5.03% today · +220.1% 1Y
Zura Bio Limited (NasdaqCM: ZURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $533.77M and employs 40 people.
Over the last twelve months the share price has gained 220.1%, trading between 1.64 and 7.44.
Tweenvest scores Zura Bio Limited across four factors: quality 30/100. Its strongest factor is quality.
ZURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $533.77M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- -0.02
- 52-week high
- $7.44
- 52-week low
- $1.64
- Avg volume (3M)
- —
- Shares outstanding
- 95.83M
- Employees
- 40
- Next earnings
- —
About Zura Bio Limited
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
- Founded
- 2022
- Listed since
- Mar 21, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.